减低剂量预处理单倍体高剂量外周血造血干细胞移植后造血及免疫重建的研究

探索减低剂量预处理亲缘间单倍体非体外去T细胞外周血造血干细胞移植（RIC-RHNT-PBSCT）技术治疗恶性血液病的方法及其可行性。针对那些年龄较大或体质较弱不适合做清髓性移植，且又无法找到HLA全相合供者的恶性血液病患者，我们设计了FAB方案作为预处理方案，采用经G-CSF动员、体外不去T细胞的供者高剂量外周血造血干细胞作为移植物进行RIC-RHNT-PBSCT，按MNC12～15×10^8/kg、15.1～20×10^8/kg分为2组，对移植后植入率、急性移植物抗宿主病发生及临床疗效进行研究，同时对移植早期免疫功能及共刺激分子的变化特点进行研究，以期成功建立独特的RIC-RHNT-PBSCT模式，使更多的患者受益。

Explore clinical efficiency and feasibility of reduced-intensity conditioning regimen to related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem cell transplantation(RIC-RHNT-PBSCT) for hematologic malignancies.For those patients who are elder or weak, not suitable for myeloablative conditioning regimen, and don't have HLA-matched donor, we design the RIC-RHNT-PBSCT, which use FAB as RIC regimen, and with G-CSF mobilizated non T cell-depleted of donor high-dose peripheral blood stem cell in vitro as graft source. According to the count of MNC, patients are divided into two groups：group A(12～15×10^8/kg) and group B (15.1～20×10^8/kg), We research engrufment ,acute graft versus host disease and clinical efficiency ; immune reconstruction and varying characteristics of co-stimulatory molecular are studied simultaneously. Hoping to establish an unique RIC-RHNT-PBSCT for curing more patients.